MATN

Mateon Therapeutics, Inc.

 
Common Stock SEC Reporting - Current
OTCQX U.S.
Verified Company Profile 6/06/2017
Contact Info
  • 701 Gateway Boulevard
  • Suite 210
  • South San Francisco, CA 94080

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0000908259
Fiscal Year End 12/31
OTC Marketplace OTCQX U.S.
Profile Data
SIC - Industry Classification 2836 - Biological products, except diagnostic
Incorporated In: DE, USA
Year of Inc. 1992
Employees 16 a/o Mar 31, 2017
Company Officers/Contacts
William D. Schwieterman CEO
Matthew M. Loar CFO
David (Dai) Chaplin CSO
Company Directors
William D. Schwieterman Chairman
David (Dai) Chaplin
Bobby W. Sandage, Jr.
Simon Pedder
Donald R. Reynolds
Company Notes
  • Formerly=OXiGENE, Inc. until 6-2016
Service Providers
OTCQX Advisor
Not Available
Accounting/Auditing Firm
OUM & Co., LLP
465 California Street
Suite 700
CA, 94104
United States

Legal Counsel
Mintz, Levin, Cohen, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA, 02111
United States

Investor Relations Firm
Not Available
MATN Security Details
Share Structure
Market Value1 $12,473,464 a/o Sep 19, 2017
Authorized Shares 70,000,000 a/o Apr 13, 2017
Outstanding Shares 26,544,934 a/o Apr 13, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 26,463,181 a/o Apr 13, 2017
Par Value Not Available
Shareholders
Shareholders of Record 40 a/o Apr 13, 2017
Short Selling Data
Short Interest 446,790 (-30.61%)
Aug 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security